Arcus Biosciences Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
8.28
-0.25
(-2.93%)
Volume:
1,185,734
52 week range:
6.50 - 18.98
Market Cap:
876.729M
Company Description:
Arcus Biosciences, Inc. develops and commercializes cancer therapies in the United States. Its product pipeline includes Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company was incorporated in 2015 and is headquartered in Hayward, California.